Soleno Therapeutics Reports Strong Commercial Launch Progress for VYKAT XR in Prader-Willi Syndrome
Key Insights
Soleno Therapeutics is targeting approximately 10% of the total addressable market, equating to about 1,000 start forms over 9-12 months for its PWS (search) treatment VYKAT XR (search).
The company has achieved better-than-expected reimbursement coverage through almost 48 Medicaid programs and Medicare, with over 600 prescribers now using the therapy.
Start forms typically convert to active patients within 30-45 days with single-digit cancellation rates, while overall discontinuation remains around 15-20%.
Soleno Therapeutics provided encouraging updates on the commercial launch of VYKAT XR (search), the first approved treatment for Prader-Willi syndrome (search) (PWS (search)), during Guggenheim (search)'s 2026 Emerging Outlook Biotech Summit. The company reported strong early momentum in patient uptake, reimbursement coverage, and prescriber adoption approximately three quarters after market launch.
Commercial Launch Metrics Show Steady Progress
CEO Anish Bhatnagar outlined the company's launch trajectory, advising investors to model roughly 10% of the total addressable market (TAM), which equates to approximately 1,000 start forms over a nine to 12-month period. The company expects quarter-to-quarter variability in these metrics and plans to discontinue reporting start-form data after the first quarter, shifting focus to more traditional revenue and active patient reporting.
CFO Jim Mackaness detailed the patient conversion process, explaining that start forms submitted by prescribers are processed through specialty pharmacy partner Panther (search) within 30 to 45 days. The conversion rate remains robust, with only single-digit cancellation rates due to administrative errors or family timing issues.
Patient Retention and Safety Profile Align with Clinical Data
Real-world discontinuation rates have tracked closely with clinical trial expectations, with overall discontinuation ranging from 15-20% and adverse event-related discontinuations at approximately 12% in the fourth quarter. Bhatnagar noted that adverse event-related discontinuations tend to occur earlier in treatment, suggesting patients who remain on therapy beyond the initial period may be more likely to persist.
The safety profile observed in commercial use appears consistent with clinical trial data and product labeling. Reported adverse events include fluid retention, hyperglycemia, rash, and hypertrichosis, with events being predominantly non-serious. While raw event counts may appear higher due to treating "almost 10 times as many patients" commercially compared to clinical trials, percentage trends remain similar to trial experience.
Reimbursement Success Exceeds Expectations
Market access has progressed better than anticipated, with coverage secured through almost 48 Medicaid programs. Medicare has emerged as "one of its best payers," according to Bhatnagar. The company has successfully removed new-to-market blocks on large pharmacy benefit managers, and policies are being written largely to align with the product label.
The reimbursement team described the launch as unprecedented in their experience, though management acknowledged potential one-off prior authorization challenges. Revenue generation depends on active paid patients, adherence rates, wholesale acquisition cost, and seasonally variable gross-to-net adjustments.
Prescriber Base Expansion and Education Focus
The prescriber network has grown beyond expectations, now encompassing more than 600 healthcare providers. However, many prescribers have limited patient volume, with only one or two PWS (search) patients each, necessitating extensive educational support. Bhatnagar described physician support sessions lasting 30-45 minutes focused on individual patient discussions, which have proven effective in some cases.
European Regulatory Progress Continues
The European regulatory review process remains on track, with Day 180 questions expected by the end of February. The potential European market represents approximately 9,500 patients across EU4 plus UK territories. Some countries, including France, route patients through designated centers of excellence, which may influence commercial strategy.
Soleno has begun building its European commercial team and expressed increasing confidence in directly addressing the market, while acknowledging ongoing partner interest. The company's capital deployment priorities include supporting both U.S. and international launches, pursuing additional indications for VYKAT, and evaluating inorganic growth opportunities, though such deals are "probably not in the short term."
Revenue Seasonality and Future Guidance
Management expects first-quarter revenue to experience seasonal effects due to higher gross-to-net discounts from insurance copay resets and coverage disruptions when patients switch plans. These factors can temporarily increase copay assistance spending and move patients from paid to free drug through bridging programs.
The company has not yet committed to providing full-year guidance, citing the need for business maturation and better understanding of launch dynamics' "ebbs and flows." However, guidance remains "on the table" once management gains sufficient comfort with operational patterns.